A transdermal absorption-type patch (10) includes: a support material (1) and an adhesive layer (2) laminated on the support material (1). The adhesive layer (2) includes: a solid composite material (2a), the solid composite material (2a) being an active ingredient with a molecular weight of 800 or greater enclosed by a surfactant; an oil phase; and an adhesive agent, the adhesive agent containing an acrylic elastomer. The content of the acrylic elastomer is 30% to 70% by mass based on the total mass of the acrylic elastomer and the oil phase. The composite material (2a) forms a solid-in-oil type particle dispersed in the oil phase.

Liquid polymer pharmaceutical compositions with a biodegradable liquid polymer, a biocompatible solvent or combination or mixture of solvents and/or co-solvents, and an active pharmaceutical agent comprising a peptide are useful to provide extended long-term release of the drug to a subject and/or to improve the stability of the active pharmaceutical agent. In embodiments, the polymer may be initiated with a low-molecular weight polyethylene glycol and/or may be a block copolymer comprising a low-molecular weight polyethylene glycol block. In further embodiments, the liquid polymer pharmaceutical composition may include a divalent cation, which may be provided in the form of a metal salt.

Methods for non-invasive retrieval of viable (i.e., able to be fertilized) oocytes from the uterus via a combination of unique ovarian stimulation and uterine lavage technology. These methods may eliminate the need for an invasive surgical procedure. Embodiments include the use of a novel hormonal protocol, including the use of injectable gonadotropins, to induce the release of immature oocytes from the ovaries of a patient. The immature oocytes mature as they transit the fallopian tubes such that mature, viable oocytes may be collected from the uterus via a uterine lavage procedure. Further embodiments include the use of a novel hormonal protocol, including the administration of Prostaglandins, Estradiol, and/or Progesterone Blockers, to accelerate transport of oocytes through the fallopian tubes. Further embodiments include kits for uterine lavage, compositions suitable for triggering and inducing superovulation, and compositions suitable for accelerating tubal transport of mature oocytes in a female patient.

Methods for non-invasive retrieval of viable (i.e., able to be fertilized) oocytes from the uterus via a combination of unique ovarian stimulation and uterine lavage technology. These methods may eliminate the need for an invasive surgical procedure. Embodiments include the use of a novel hormonal protocol, including the use of injectable gonadotropins, to induce the release of immature oocytes from the ovaries of a patient. The immature oocytes mature as they transit the fallopian tubes such that mature, viable oocytes may be collected from the uterus via a uterine lavage procedure. Further embodiments include the use of a novel hormonal protocol, including the administration of Prostaglandins, Estradiol, and/or Progesterone Blockers, to accelerate transport of oocytes through the fallopian tubes. Further embodiments include kits for uterine lavage, compositions suitable for triggering and inducing superovulation, and compositions suitable for accelerating tubal transport of mature oocytes in a female patient.

The present disclosure relates to a novel method of treatment of a cancer patient in which the patient is subjected to both an inhibitor of an immune check point molecule, preferably “Programmed Death 1” (PD-1) or its ligand “programmed death ligand 1” (PD-L1), and a Gonadotropin-Releasing Hormone (GnRH, also known as LHRH or FSH-RH) agonist or antagonist.

The present disclosure relates to a novel method of treatment of a cancer patient in which the patient is subjected to both an inhibitor of an immune check point molecule, preferably “Programmed Death 1” (PD-1) or its ligand “programmed death ligand 1” (PD-L1), and a Gonadotropin-Releasing Hormone (GnRH, also known as LHRH or FSH-RH) agonist or antagonist.

The present invention provides compositions and methods that provide a high degree of sensitivity and a high degree of specificity for the non-invasive assessment of endometriosis in women having a variety of endometriosis types (e.g., endometriosis, endometriotic cysts, endometrioma, or another benign condition of the endometrium) and at a variety of disease states (e.g., early and late stage).

The present invention provides compositions and methods that provide a high degree of sensitivity and a high degree of specificity for the non-invasive assessment of endometriosis in women having a variety of endometriosis types (e.g., endometriosis, endometriotic cysts, endometrioma, or another benign condition of the endometrium) and at a variety of disease states (e.g., early and late stage).

The present disclosure describes a GnRH therapeutic for neutralizing GnRH levels in subjects which can reduce testosterone levels to attenuate or eliminate prostate cancer cell growth and/or metastasis. The therapeutic is produced synthetically. The GnRH therapeutic includes a hapten carrier (hC) comprising a monomeric peptide (MP), synthesized separately from the GnRH peptide, and following self-assembly of the hC, GnRH is covalently coupled to form a GnRH-hC conjugate which can serve as a therapeutic. The MP includes heptad repeats following a specific pattern. The hC can include a GnRH peptide attached to a monomeric peptide prior to self-assembly to form a therapeutic. Optionally, the GnRH-hC conjugate further includes one or more T-cell epitopes at the N- and/or C-terminus of the one or more amphipathic alpha-helices. The present disclosure also describes compositions including immunogenic compositions including the therapeutics described herein.

The present disclosure describes a GnRH therapeutic for neutralizing GnRH levels in subjects which can reduce testosterone levels to attenuate or eliminate prostate cancer cell growth and/or metastasis. The therapeutic is produced synthetically. The GnRH therapeutic includes a hapten carrier (hC) comprising a monomeric peptide (MP), synthesized separately from the GnRH peptide, and following self-assembly of the hC, GnRH is covalently coupled to form a GnRH-hC conjugate which can serve as a therapeutic. The MP includes heptad repeats following a specific pattern. The hC can include a GnRH peptide attached to a monomeric peptide prior to self-assembly to form a therapeutic. Optionally, the GnRH-hC conjugate further includes one or more T-cell epitopes at the N- and/or C-terminus of the one or more amphipathic alpha-helices. The present disclosure also describes compositions including immunogenic compositions including the therapeutics described herein.